2003 Treatment Trials Virus 
The Pharma Data
MARCH 8, 2021
The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture.
The Pharma Data
DECEMBER 23, 2020
Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. All study subjects will receive the same Ampligen treatments. development pipeline for ME/CFS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIH Director's Blog: Drug Development
MARCH 18, 2021
Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. And, how can those structural differences serve as blueprints for promising new treatments to combat many potentially deadly viruses?
PLOS: DNA Science
JULY 27, 2023
That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus.
NIH Director's Blog: Drug Development
MAY 21, 2020
B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. Because of these and other factors, many experts think antibody-based therapies may offer one of the best near-term options for developing safe, effective treatments for COVID-19. In the U.S.
The Pharma Data
NOVEMBER 23, 2020
The study is an open-label, exploratory phase I/II trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (and later) line treatment of MPM to assess safety, immune activation and efficacy versus SoC only. OSLO, Norway , Nov. The next survival analysis is planned in first half of 2021. References.
The Pharma Data
APRIL 25, 2021
Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. The overall safety profile of nirsevimab in the trial remains consistent with previously reported results.
Expert insights. Personalized for you.
69 
Let's personalize your content